Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1145-1151

  Huang, Yu Chung ^a,b   Liu, Chia Jen ^a,b   Liu, Chun Yu ^a,b   Pai, Jih Tung ^a,b   Hong, Ying Chung ^a,b   Teng, Hao Wei ^a,b   Hsiao, Liang Tsai ^a,b   Chao, Ta Chung ^a,b   Gau, Jyh Pyng ^a,b   Liu, Jin Hwang ^a,b   Hsu, Hui Chi ^a,b   Chiou, Tzeon Jye ^a,b   Chen, Po Min ^a,b   Yu, Yuan Bin ^a,b   Tzeng, Cheng Hwai ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Absolute lymphocyte count; Diffuse large B cell lymphoma; Interstitial pneumonia; Rituximab

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; CHINA; COHORT ANALYSIS; DISEASE PREDISPOSITION; DRUG MONITORING; INCIDENCE; INTERSTITIAL LUNG DISEASE; LYMPHOCYTOPENIA; MIDDLE AGED; PATHOPHYSIOLOGY; SURVIVAL;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; COHORT STUDIES; DISEASE SUSCEPTIBILITY; DRUG MONITORING; FEMALE; HUMANS; INCIDENCE; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPENIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 80055074784     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1268-2     Document Type: Article

References (37)

1. Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359:613-626
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242 (Pubitemid 34438862)
3. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
4. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 94:2217-2224 (Pubitemid 29467667)
5. Rafailidis PJ, Kakisi OK, Vardakas K, Falagas ME (2007) Infectious complications of monoclonal antibodies used in cancer therapy. Cancer 109:2182-2189
6. Lin PC, Hsiao LT, Poh SB, Wang WS, Yen CC, Chao TC et al (2007) Higher fungal infection rate in elderly patients (more than 80-years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol 86:95-100
7. Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 49:1778-1783
8. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D (2007) Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92:139-140 (Pubitemid 46232678)
9. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS (2010) High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 51:797-801
10. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K et al (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87:393-397
11. Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Yet al (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50:1818-1823
12. Burton C, Kaczmarski R, Jan-Mohamed R (2003) Interstitial pneumonitis related to rituximab therapy. N Engl J Med 348:2690-2691 (Pubitemid 36741603)
13. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA (2006) Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17:372-379 (Pubitemid 43329572)
14. Ghesquieres H (2005) Severe interstitial pneumonitis following rituximab and bleomycin-containing chemotherapy. Ann Oncol 16:1399 (Pubitemid 41158487)
15. Ray-Coquard I, Cropet C, Van GM, Sebban C, Le CA, Judson I et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383-5391
16. Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P et al (2010) Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 21:1486-1491
17. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ et al (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22:149-155
18. Borg C, Ray-Coquard I, Philip I, Clapisson G, Driss-Vermare N, Menetrier-Caux C et al (2004) CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 101:2675-2680 (Pubitemid 39532301)
19. Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K (1996) Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 14:1071-1076 (Pubitemid 26105511)
20. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE (2001) Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 42:1329-1337 (Pubitemid 34082922)
21. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833 (Pubitemid 28363048)
22. Dales JP, Plumas J, Palmerini F et al (2001) Correlation between apoptosis microarray gene expression profiling and histopathological lymph node lesions. Mol Pathol 54:17-23 (Pubitemid 32128423)
23. Lan Q, Zheng T, Chanock S et al (2007) Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 28:823-827 (Pubitemid 46523339)
24. Shin MS, Kim HS, Kang CS et al (2002) Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99:4094-4099 (Pubitemid 35332052)
25. Lan Q, Morton LM, Armstrong B et al (2009) Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood 114:264-267
26. Soung YH, Lee JW, Kim SY et al (2004) Somatic mutations of CASP3 gene in human cancers. Hum Genet 115:112-115 (Pubitemid 39010925)
27. Bethke L, Sullivan K, Webb E et al (2008) The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev 17:987-989 (Pubitemid 351536434)
28. Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352-358 (Pubitemid 46328496)
29. MacPherson G, Healey CS, Teare MD et al (2004) Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 96:1866-1869 (Pubitemid 40081324)
30. Son J-W, Kang H-K, Chae MH et al (2006) Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet 169:121-127 (Pubitemid 44287103)
31. Sun T, Gao Y, Tan W et al (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39:605-613 (Pubitemid 46676113)
32. Frank B, Rigas SH, Bermejo JL et al (2008) The CASP8-652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 111:139-144 (Pubitemid 352009221)
33. Haiman CA, Garcia RR, Kolonel LN et al (2008) A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 40:259-260, author reply 260-261
34. Zou Y, Zeng Y, Zhang DF et al (2010) IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun 402:378-383
35. Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169 (Pubitemid 37414228)
36. Wang M, Zhang Z, Tian Y et al (2009) A six-nucleotide insertiondeletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res 15:2567-2572
37. Ni C, Ye Y, Wang M et al (2009) A six-nucleotide insertiondeletion polymorphism in the CASP8 promoter is associated with risk of coal workers' pneumoconiosis. J Toxicol Environ Health A 72:712-716